Immature teratoma

Summary

Immature teratoma (MONDO:0024746) is a disease and 1 clinical trial. Top therapeutic interventions include ifosfamide. A subtype of teratoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	immature teratoma
Mondo ID	MONDO:0024746
NCIT	C4286
UMLS	C0334520
MedGen	90798
GARD	0025461
Is cancer (heuristic)	no

Also known as: embryonal teratoma · hrade 2 Teratoma · immature teratoma

Disease family

This is a subtype of teratoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › germ cell tumor › nongerminomatous germ cell tumor › teratoma › immature teratoma

Related subtypes (12): cystic teratoma, central nervous system teratoma, gastric teratoma, malignant teratoma, fallopian tube teratoma, adult teratoma, mature teratoma, mediastinum teratoma, gonadal teratoma, teratoma with malignant transformation, nasopharyngeal teratoma, sacrococcygeal teratoma

Subtypes (3): pineal region immature teratoma, immature teratoma of vulva, immature extragonadal teratoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04684368	PHASE2	RECRUITING	A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
IFOSFAMIDE	4	1